Health care equipment & supplies
Convatec is a global medical-products company focused on chronic conditions. Its products are used in wound care, ostomy care, continence care and infusion therapy, where repeat use and long-term patient needs create recurring demand.
Advanced wound dressings, ostomy products, continence and critical-care products, infusion sets and related medical technologies, supported by manufacturing, clinical development and patient-support services.
Healthcare systems and patients across more than 90 countries, with substantial exposure to North America and Europe and sales through hospitals, clinics, distributors and home-care channels.
Growth in chronic disease, ageing populations, new product launches, market-share gains, reimbursement, manufacturing efficiency, pricing and execution of the Accelerate strategy.
Reimbursement changes, product or regulatory issues, pricing pressure, healthcare-budget constraints, manufacturing disruption, competitive innovation and dependence on successful launches in specialist medical categories.
21 May 2026: Convatec reiterated 2026 guidance for 5-7% organic revenue growth excluding InnovaMatrix and an adjusted operating margin of at least 23%. The group is also rolling out its Accelerate strategy and a pipeline of new products.
Normally pays interim and final dividends in US cents. The 2025 final dividend of 5.367 cents went ex-dividend on 16 April 2026 and was paid on 28 May, taking the full-year dividend to 7.244 cents. The 2026 interim timetable should be checked following the August half-year results.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.